ProMIS Neurosciences (
TSX: PMN,
Forum) advanced its ground-breaking Alzheimer’s (AD) therapy when the company announced today that it had identified and submitted a provisional patent application for a fifth novel therapeutic target on prion-like strains of misfolded Amyloid beta (Ab), implicated in the development and progression of AD.
According to the
news release, the company used its unique, proprietary discovery platforms, ProMIS™ and Collective Coordinates, to identify this fifth, novel target and has filed a provisional patent application to the United States Patent Office on June 20, 2016.
Company CEO, Dr. Elliot Goldstein, commented on the milestone, “Multiple therapeutic candidates against all five of the novel targets we have identified demonstrated, during the screening phase, selective binding to misfolded strains of Amyloid beta, with no measurable off-target binding.”
He then summed up, “These candidates are currently being evaluated for their binding profiles in cadaveric brain tissue from patients with a confirmed diagnosis of Alzheimer's. We are looking forward to the results of these validation studies, which will enable the selection of therapeutic products for drug development.”
ProMIS Neurosciences was in the news recently when
the company’s science team commented on a recent Alzheimer’s study a little over a week ago that shed new light on prions.
Shares rocketed 40.91% to $0.155 per share.
Currently there are 164.50m outstanding shares with a market cap of $18.10 million.
FULL DISCLOSURE: ProMIS Neurosciences is a Stockhouse Publishing client.